Please wait while the formulary information is being retrieved.
LEUKINE (sargramostim)
- Delay or failure of allogenic bone marrow transplant
- Delay or failure of autologous bone marrow transplant
- Hematopoietic syndrome of acute radiation syndrome
- Myeloid engraftment enhancement
- Myeloid engraftment enhancement post aut PBPC transplant
- Neutropenia secondary to AML treatment
- Peripheral mobilization of hematopoietic stem cells
250 mcg solution for injection
- Inject 250 mcg/m2 by subcutaneous route once daily
Delay or failure of allogenic bone marrow transplant
- Infuse 125 mcg/m2 over 2 hour(s) by intravenous route once daily
- Infuse 125 mcg/m2 over 2 hour(s) by intravenous route once daily for 14 days
- Infuse 250 mcg/m2 over 2 hour(s) by intravenous route once daily
- Infuse 250 mcg/m2 over 2 hour(s) by intravenous route once daily for 14 days
- Infuse 500 mcg/m2 over 2 hour(s) by intravenous route once daily
- Infuse 500 mcg/m2 over 2 hour(s) by intravenous route once daily for 14 days
Delay or failure of autologous bone marrow transplant
- Infuse 125 mcg/m2 over 2 hour(s) by intravenous route once daily
- Infuse 125 mcg/m2 over 2 hour(s) by intravenous route once daily for 14 days
- Infuse 250 mcg/m2 over 2 hour(s) by intravenous route once daily
- Infuse 250 mcg/m2 over 2 hour(s) by intravenous route once daily for 14 days
- Infuse 500 mcg/m2 over 2 hour(s) by intravenous route once daily
- Infuse 500 mcg/m2 over 2 hour(s) by intravenous route once daily for 14 days
Drug-induced neutropenia
- Inject 250 mcg/m2 by subcutaneous route once daily
- Inject 5 mcg/kg by subcutaneous route once daily
- Infuse 250 mcg/m2 over 4 hour(s) by intravenous route once daily
Hematopoietic syndrome of acute radiation syndrome
- Inject 7 mcg/kg by subcutaneous route once daily
Myeloid engraftment enhancement
- Infuse 125 mcg/m2 over 2 hour(s) by intravenous route once daily
- Infuse 250 mcg/m2 over 2 hour(s) by intravenous route once daily
Myeloid engraftment enhancement post aut PBPC transplant
- Inject 250 mcg/m2 by subcutaneous route once daily
- Inject 125 mcg/m2 by subcutaneous route once daily
- Infuse 250 mcg/m2 over 24 hour(s) by intravenous route once daily
- Infuse 125 mcg/m2 over 24 hour(s) by intravenous route once daily
Neutropenia secondary to AML treatment
- Infuse 250 mcg/m2 over 4 hour(s) by intravenous route once daily
- Infuse 125 mcg/m2 over 4 hour(s) by intravenous route once daily
Peripheral mobilization of hematopoietic stem cells
- Inject 250 mcg/m2 by subcutaneous route once daily
- Inject 125 mcg/m2 by subcutaneous route once daily
- Infuse 250 mcg/m2 over 24 hour(s) by intravenous route once daily
- Infuse 125 mcg/m2 over 24 hour(s) by intravenous route once daily
- None
Contraindicated
- None
Severe
Moderate
- Hycamtin
- topotecan
- None
Contraindicated
- Capillary leak syndrome
- Cardiac arrhythmia
- Edema
- Heart failure
- Pericardial effusion
- Pleural effusions
- Pre-existing fluid retention
- Pulmonary infiltrates
Severe
Moderate
- Leukocytosis
LEUKINE (sargramostim)
- Delay or failure of allogenic bone marrow transplant
- Delay or failure of autologous bone marrow transplant
- Hematopoietic syndrome of acute radiation syndrome
- Myeloid engraftment enhancement
- Myeloid engraftment enhancement post aut PBPC transplant
- Neutropenia secondary to AML treatment
- Peripheral mobilization of hematopoietic stem cells
- Hypertension
- Arthralgias
- Bone pain
- Headache disorder
- Myalgias
- Pruritus of skin
- Skin rash
- Vomiting
- Weight loss
More Frequent
Severe
Less Severe
- Abnormal hepatic function tests
- Body fluid retention
- Fever
- Hyperbilirubinemia
- Leukocytosis
- Pericardial effusion
- Pleural effusions
- Sepsis
- Alopecia
- Diarrhea
- Dyspnea
- Edema
- Injection site sequelae
- Insomnia
- Malaise
- Peripheral edema
- Pharyngitis
- Stomatitis
- Symptoms of anxiety
- Tachycardia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Capillary leak syndrome
- Eosinophilia
- Hypotension
- Pericarditis
- Shortened time to tumor progression
- Supraventricular arrhythmias
- Thromboembolic disorder
- Thrombophlebitis
- Vasculitis
Less Severe
- Acute abdominal pain
- Chest pain
- Erythema
- Flushing
- General weakness
- Syncope
- Urticaria
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Sargramostim
Limited safety data. May use for acute radiation exposure. May contain benzyl alcohol.
- 1 Day – 2 Years
- Limited safety data. May use for acute radiation exposure. May contain benzyl alcohol.
Sargramostim
- Severity Level:
2
- Additional Notes: Insufficient human data available. animal data suggest developmental toxicity.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Sargramostim
None
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Delay or failure of allogenic bone marrow transplant | |
| T86.02 | Bone marrow transplant failure |
| Delay or failure of autologous bone marrow transplant | |
| T86.02 | Bone marrow transplant failure |
| Hematopoietic syndrome of acute radiation syndrome | |
| T66.xxxA | Radiation sickness, unspecified, initial encounter |
| T66.xxxD | Radiation sickness, unspecified, subsequent encounter |
| Neutropenia secondary to AML treatment | |
| D70.1 | Agranulocytosis secondary to cancer chemotherapy |
| Peripheral mobilization of hematopoietic stem cells | |
| Z52.011 | Autologous donor, stem cells |
| 0-9 | A-Z |
|---|---|
| D70.1 | Agranulocytosis secondary to cancer chemotherapy |
| T66.xxxA | Radiation sickness, unspecified, initial encounter |
| T66.xxxD | Radiation sickness, unspecified, subsequent encounter |
| T86.02 | Bone marrow transplant failure |
| T86.02 | Bone marrow transplant failure |
| Z52.011 | Autologous donor, stem cells |
Formulary Reference Tool